A Double-Blind, Placebo-Controlled, Cross-Over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy.
Phase of Trial: Phase IV
Latest Information Update: 02 Sep 2014
At a glance
- Drugs Ranolazine (Primary)
- Indications Polyneuropathy
- Focus Therapeutic Use
- Sponsors CV Therapeutics; Gilead Sciences
- 09 Dec 2009 CV Therapeutics company acqiured by Gilead Sciences hence replaced in assocation field as sponsor and affiliate as reported by ClinicalTrials.gov.
- 16 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Feb 2009 New trial record